|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5810 USD | -0.26% |
|
-3.23% | +0.16% |
| Feb. 27 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Dec. 18 | RTW Biotech Opportunities announces new investment in Yarrow Bioscience | RE |
Executive Committee: VYNE Therapeutics Inc.
| Manager | Positions heldSince | ||||||
|---|---|---|---|---|---|---|---|
![David Domzalski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>) David Domzalski 60 year |
| ||||||
Iain Stuart 53 year |
| ||||||
Mutya Harsch 52 year |
| ||||||
Tyler Zeronda 40 year |
|
Composition of the Board of Directors: VYNE Therapeutics Inc.
| Director | CommitteesSince | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Elisabeth Little Sandoval 64 year |
| ||||||||
Sharon Barbari 72 year |
| ||||||||
Pat LePore 71 year |
| ||||||||
Steven Basta 61 year |
| ||||||||
David Domzalski 60 year |
|
Latest Appointments: VYNE Therapeutics Inc.
Former Officers and Directors: VYNE Therapeutics Inc.
| Insider | Positions held SinceUntil | ||||||
|---|---|---|---|---|---|---|---|
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
|
Age distribution of managers
Parity Men Women
| Male | 5 |
|---|---|
| Female | 3 |
Of which Executive Committee
| Male | 3 |
|---|---|
| Female | 1 |
Of which Directors
| Male | 3 |
|---|---|
| Female | 2 |
Select your edition
All financial news and data tailored to specific country editions
